It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A clinical-stage pharma company focused on developing life-transforming treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways
- Lead asset Nomacopan= in P2-3 of development for disease targets across dermatology, hematology, and pulmonology
- Nomacopan has also been tested in P2-3 trials for PNH